RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty.

IV or inhaled THC: Works quickly with high peak, feel euphoric but not sustained response Oral is much better for medicinal usage @RheumNow #ACR24 https://t.co/3PatgEFjZh https://t.co/wrrLMpfL5D

• https://x.com/ericdeinmd/status/1857815283110445214/photo/1
• https://x.com/ericdeinmd/status/1857815283110445214/photo/1
• https://twitter.com/ericdeinmd/status/1857813738260148641

Cool data from the JAK-POT study Have heard JAKs faster than TNF; perhaps not the case! If anything, TNFs outperformed the others in this study Trying not to over-read this, but supports my re-emerging preference for TNF #ACR24 @rheumnow Abstr#0501 https://t.co/NDyPwju3ds

• https://x.com/EBRheum/status/1857813881176854579/photo/1
• https://x.com/EBRheum/status/1857813881176854579/photo/1

How to take cannabis? Do NOT rec inhaled - makes drug level go up high/fast, benefit for rec use but not for medicinal - bronchitis, ?oral cancer Other risks: psychosis - risk in youth, memory loss (poor studies), dependence, respiratory if inhaled Clauw 16S18 #ACR24 @RheumNow https://t.co/coYNl7VOT3

• https://x.com/ericdeinmd/status/1857813738260148641/photo/1

#0513 🔬 Rituximab in RA: IgG levels & infection ➡️ 164 patients (mean age 59, IgG 14g/L, dx duration 13yrs) 🧬 IgG levels ⬇️over time (6 years/25 infusions) ⚠️ Infection-related hospitalizations peaked year 1 ⬆️risk w/ concurrent steroid(HR 2.1,p=0.002) #ACR24 @RheumNow

Older adults with RA receive less DMARDs, the standard of care. Dr. Bruno Fautrel shows TOC tolerance in older adults is comparable to younger patients. Let's treat the patient, not their age! #ACR24 @RheumNow ABST#0516 https://t.co/054RWGh3a7

• https://x.com/JihaRheum/status/1857813377805893719/photo/1

Discrimination in #SLE is a chronic stressor - Asians had substantial levels along with association of worse mental health and SLE activity Data from the California Lupus Epidemiology Study (CLUES) using the Everyday Discrimination Scale (EDS) @JYazdany @RheumNow #ACR24 abst#0171

Clauw: think of THC and CBD as “completely different” Cannabidiol - safe, not psychoactive, “can use liberally” THC - psychoactive with effects on CB1 and CB2 receptors. CB1 affects the brain where CB2 is more in inflammation #ACR24 @RheumNow https://t.co/A0TgSpAO64

• https://x.com/ericdeinmd/status/1857812843136954401/photo/1
• https://x.com/ericdeinmd/status/1857812843136954401/photo/1

Cardiology 🤝 Rheumatology #Abstract0611 highlights Subclinical atherosclerosis (carotid plaque > 1.5 mm) associated with ↑ risk of CV events in SLE longitudinal cohort @RheumNow #ACR24 https://t.co/jLLYNOfFZ2

• https://x.com/AkhilSoodMD/status/1857812622797578650/photo/1

Moderating a great talk about POTS - great slide & nice presentation technique Dr. Adler flashed a screen of the ROS for pts w/POTs, overwhelming as expected… then overlaid common causes and phenotypes - really like this as a framework! #ACR24 @RheumNow https://t.co/mCmtygxxv4

• https://x.com/EBRheum/status/1857812262070714500/photo/1

🚨Therapeutic target in PsO? Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO). - HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4. - Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI

• https://x.com/i/web/status/1857812119649136924
• https://x.com/AdelaCastro222/status/1857812119649136924/photo/1
• https://x.com/AdelaCastro222/status/1857812119649136924/photo/1

Implementing an automated inflammatory back pain screening tool in community rheumatology practices significantly enhances the identification of axial spondyloarthritis. With 14.3% of positive screenings leading to diagnosis. Another innovation that may help with the rapid… https://t.co/qSwryK22uj

• https://x.com/i/web/status/1857812119326183889

#0456📱 Digital Health & RA ePROs 💻Rx response in 150 RA patients using ePROs & actigraphy 🔍Actigraphy slightly improved accuracy (86% precision, 83% v. 75% recall with ePROs alone) 💡Passive actigraphy can help classify response &⬇️ ePROs, patient burden. #ACR24 @RheumNow

🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure: -Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie #ACR24 @RheumNow https://t.co/Jc0cdmrVhI

• https://x.com/AdelaCastro222/status/1857810860795638038/photo/1